Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting.

Yahya AlmodallalJennifer G Le-RademacherKathryn D CookSiddhartha YadavAmrit B SinghMinji LeeLisa M LammertAminah Jatoi

Published in: Breast cancer research and treatment (2021)

Older patients might derive further benefit from alpelisib if the adverse event profile of this agent, particularly the hyperglycemia, were able to be better managed.

Keyphrases

clinical trial
phase ii
study protocol
double blind
emergency department
phase iii
adverse drug